Our Science

Publications and Presentations

search
Date
Title
October 2023
SCY-247, A SECOND-GENERATION IV/ORAL TRITERPENOID ANTIFUNGAL: IN VITRO ACTIVITY AGAINST A BROADSPECTRUM OF FUNGAL PATHOGENS, AND DOSE-DEPENDENT TISSUE DISTRIBUTION IN VIVO TIMM, October 2023
April 2023
Outcomes of Oral Ibrexafungerp in Subjects with Urinary Tract Infections from Two Phase 3 Open Label Studies: Difficult to Treat Invasive Fungal Infections (FURI) and Infections with Candida auris (CARES) ECCMID, April 2023
April 2023
FURI Study: Outcomes in Subjects with Intraabdominal Candidiasis Treated with Oral Ibrexafungerp ECCMID, April 2023
April 2023
A Novel Protocol Design to Study the Efficacy and Safety of Oral Ibrexafungerp as Step Down Therapy following Intravenous (IV) Echinocandin for the Treatment of Invasive Candidiasis (MARIO): Developing a Paradigm Shift to IV and Oral Anti-Cell Wall Therapy ECCMID, April 2023
October 2022
All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI) IDWeek
September 2022
Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI) ISHAM
September 2022
Outcomes of Oral Ibrexafungerp in Refractory Patients with Candida from an Interim Analysis of a Phase 3 Open-Label Study (FURI) MSGERC
September 2022
Outcomes of Oral Ibrexafungerp in the Treatment of 18 Patients with Candida auris Infections, from the CARES Study MSGERC
September 2022
CANDLE: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Once Monthly Oral Ibrexafungerp for Prevention of Recurrent Vulvovaginal Candidiasis (VVC) NPWH
September 2022
All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Ibrexafungerp Open-label Study (FURI) ISHAM
< Prev Next >